Bladder cancer drug Balversa offers new treatment option
By Whang, byung-woo | translator Alice Kang
24.10.18 05:47:26
가나다라
0
First targeted therapy approved by the US FDA and in Korea for urothelial cancer
Phase III study shows a 36% reduction in risk of death and improved PFS and OS compared to chemotherapy
Experts emphasize the importance of early detection of FGFR mutations
The introduction of the targeted therapy Balversa (erdafitinib) in urothelial carcinoma has attracted attention for its potential to address unmet needs.
In particular, the emergence of FGFR inhibitors has highlighted the importance of genetic mutation diagnostics to quickly detect the presence of such mutations.
▲(from the left) Professor Tae-Jung Kim, Professor Inho Kim, BU director Yeon-Hee Kim
Inho Kim, professor of Oncology at Seoul St. Mary's Hospital, and Tae-Jung Kim, professor of pathology at Yeouido St. Mary's Hospital, emphasized the importance of diagnosing FGFR mutations at a press conference held by Janssen Korea on the 16th, which was held to celebrate the launch of Balversa.
Balversa was approved by the Ministry of Food and Drug Safet
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)